You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗:內地首發線上醫療諮詢文件 政策升至國家級別 看好平安好醫生及阿里健康
阿思達克 04-16 12:17
就發改委近日公布《關於推進「上雲用數賦智」行動培育新經濟發展實施方案》,花旗發表報告指,為內地首次對線上醫療作出諮詢文件,並提升至國家級別的層面,當局指會探索及推廣線上醫療諮詢。

該行指,自去年12月已對內地立法線上銷售處方藥合法化看法正面,部份份已有線上醫療諮詢先導計劃,而今年3月國家醫療保障局出台鼓勵對常見疾病及慢性疾病線上醫療諮詢的指引,該行料內地未來對線上醫療諮詢及藥品銷售會越趨重要。

在新冠疫情影響下,花旗認為內地政府會出台措施以支持線上醫療諮詢,中國目前線上銷售藥物的滲透率僅6%、線上醫療諮詢滲透率僅7%,料至2025年線上銷售藥物及線上醫療諮詢的滲透率可分別提升至15%及23%。

花旗指,在新冠疫情爆發之前,該行於今年初已指出中國線上醫駕板塊屬首選行業,料可受惠於內地對醫療系統的結構性改革,該行持續極為看好互聯網醫療企業包括阿里健康(00241.HK)及平安好醫生(01833.HK),均予「買入」評級,分別予目標價20元及92.8元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account